The Catalyst

Most Recent Posts

05.19.14 | By John Castellani

Last week, after an election process that took more than a month to complete with a record 550 million votes cast, the Indian people elected a new Prime Minister in a landslide election that unseated the country’s ruling Congress party.  Narendra Modi and the Bharatiya Janata Party (BJP) won enough seats in the lower house of Parliament to form a government.


Our member companies strive every day to bring innovative new medicines and treatments into the market to improve the lives of patients, both in the United States and abroad.  Access to high-quality medicines is our common goal and top priority. Unfortunately, some health plans now being offered make it more difficult for people to get access to the medicines they need.


There have been a lot of discussions lately about the value and cost of cancer medicines – it is also an issue that will be raised at the upcoming American Society of Clinical Oncology’s (ASCO) annual meeting. 

05.12.14 | By Kristin Van Goor

Using new authority granted by the Food and Drug Administration Safety and Innovation Act (FDASIA), the Food and Drug Administration (FDA) issued d


Biopharmaceutical innovators work every day to build a robust pipeline and develop new medicines that help patients cope with some of the most debilitating diseases. This week, we released a new Medicines in Development report on mental health disorders that discussed a number of new approaches being pursued in order to treat these conditions. Currently, an estimated 61.5 million Americans suffer from mental illness, or one in every four U.S.


So often the value of medicines gets lost in media reports when the focus is almost exclusively on cost.

Are we as a society willing to accept the fact that medicines, while not always inexpensive, provide great return on value because a child’s life has been saved or a friend was able to beat cancer? 

05.07.14 | By John Castellani

Each year at the National Prescription Drug Abuse Summit, discussions take place regarding the latest resources and tools for states, pharmacists, physicians, and law enforcement to use in combating the misuse and abuse of prescription medicines.

05.01.14 | By Jay Taylor

Yesterday’s release of the Special 301 report by the Office of the United States Trade Representative (USTR) once again underscores the challenges faced by innovators when confronted with deteriorating protections for intellectual property across the globe.

04.30.14 | By Leslie Chambers

As we continue to celebrate Parkinson’s Awareness Month with our recent Medicines in Development for Parkinson’s Disease report and our Conversations forum with leaders from the Parkinson’s community, today we also have a guest post from another voice in the community.

04.29.14 | By Preet Bilinski

Parkinson's is chronic and progressive, meaning that symptoms continue and can increase over time. The progression of Parkinson’s disease varies and is different for everyone. No one can predict which symptoms will affect an individual, and the intensity of the symptoms also varies. With April being Parkinson’s Awareness Month part of our efforts include reaching out to the community to hear their Parkinson stories.

04.28.14 | By Stephanie Fischer

I was grateful to have an opportunity to explain in a guest blogpost for Global Genes how the Food and Drug Administration’s (FDA) recent draft guidance on social media could have a direct impact on the ability of me and other patients to get i

04.28.14 | By Mark Elliot

Following is a guest blog from Mark Elliot, Executive Director of the Global Intellectual Property Center, where he discusses the importance of intellectual property in global trade agreements and how the U.S. has a full agenda in dealing with IP issues this year.

04.25.14 | By Christian Clymer

Tomorrow, April 26th, is the YMCA’s Healthy Kids Day, which promotes the important role an active and healthy lifestyle plays in the overall wellbeing of every child. Through various events during the day, the YMCA will emphasize how beneficial it is to stay active throughout the summer.

04.24.14 | By Randy Burkholder

The questions on cost and value are important, but they miss the opportunity to reach consensus, patient-centered solutions. Read the four places the discussions focused on cost often run amiss:


When #PhRMA14 concluded last week, we walked away from our 56th Annual Meeting with new ideas and perspectives to keep pushing the industry forward. The speakers and attendees discussed a number of important topics, and this week we focused on the value of and access to innovative medicines for patients in need.